NCE-1 Intelligence & Market Opportunity

Palsonify

Paltusotine

Hormonal Therapy

Oral Tablet

Palsonify is an oral somatostatin receptor agonist approved for adults with acromegaly. It suppresses excess growth hormone and IGF-1 levels, providing a once-daily, non-injectable alternative to traditional therapies.

Approval Date

25-Sep-25

NCE-1 Date

25-Sep-29

NCE Date

25-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

221.32%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

166

2028

327

2029

533

2030

782

2031

1,040

2032

1,286

Molecule profile

Details & specifications

Molecule

Paltusotine

Innovator

CRINETICS PHARMA INC

Dosage Form

Oral Tablet

Strength

20 mg and 30 mg

Therapeutic Category

Hormonal Therapy

Usage

To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets